The ready-to-use lentiviral particles of Lenti-EBNA3C TCR-VP is packaged using 3rd generation of lentiviral packaging system, in which the gene of Human TCR will be driven by a CMV promotor. The target gene of TCR packaged in lentiviral particles could be used for high efficency tranduction of T cells and stably integrated expression.


  • Type of Therapeutics
  • T cell receptor
  • Target
  • EBNA3C
  • Promotor
  • CMV
  • Packaging System
  • Lentivirus
  • Packaging Cell
  • 293T
  • Targeting Diseases
  • EBV infection


  • Introduction
  • Plays an essential role for the activation and immortalization of human B-cells. Represses transcription of viral promoters TP1 and Cp through interaction with host RBPJ, and inhibits EBNA2-mediated activation of these promoters. Since Cp is the promoter for all EBNA mRNAs, EBNA6 probably contributes to a negative autoregulatory control loop. Alternatively, EBNA6 also regulates the transcription of the EBV oncogene LMP1 in a cell cycle-dependent manner. Modulates the activity of several host proteins involved in cell cycle regulation including host cyclin A, MYC, RB, p21 and p27 mainly through binding to the host SCF(SKP2) complex. Inhibits the promoter of host H2AX and targets H2AX to proteasomal degradation in order to promote latency and cell proliferation.
  • Alternative Names
  • EBNA3C; Epstein-Barr nuclear antigen 3C; EBNA6; EBV nuclear antigen 6

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Related Products

Online Inquiry


45-1 Ramsey Road, Shirley, NY 11967, USA
Call us at:
USA: 1-631-381-2994
Europe: 44-207-097-1828
Fax: 1-631-207-8356

Online Inquiry

For any technical issues or products/services related questions, please leave your contacts as below, and our team will contact you at earliest convenience to let you know how we can be involved in your projects.

  • Verification code

Key Updates

Receive the latest news and insights to your inbox.